Enteritis regionalis - 100 Years after the first description of the disease;Odcinkowe zapalenie jelit w 100 lat od pierwszego opisu choroby

Gastroenterologia Polska

Volumn 11, Issue 6, 2004, Pages 615-623

  Kempiński, Radosław ^a   Paradowski, Michał ^a   Paradowski, Leszek ^a  

^a Kat/Klin Gastroenterol/Hepatol   (Poland)

Author keywords

Crohn; Enteritis regionalis; Ileitis terminalis; Le niowski

Indexed keywords

ALICAFORSEN; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PLACEBO; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 10; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; THALIDOMIDE;

CARD15 GENE; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; GENE; HUMAN; ILEITIS; ILEITIS TERMINALIS; IMMUNOSUPPRESSIVE TREATMENT; NOD2 GENE; REVIEW; STEROID THERAPY;

EID: 11244304440     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Crohn B.B., Ginzburg L., Oppenheimer G.D.: Regional ileitis: a pathologic and clinical entity. JAMA, 1932, 99, 1323-1329.
2. Szarejko P.: Stownik lekarzy polskich XIX wieku. Wydawnictwo Naukowe Semper, Warszawa 1994, 161-163.
3. Leśniowski A.: Przyczynek do chirurgii kiszek. Med., 1903, 21, 460-464.
4. Leśniowski A.: Przyczynek do chirurgii kiszek. Med., 1903, 22, 483-489.
5. Leśniowski A.: Przyczynek do chirurgii kiszek. Med., 1903, 23, 514-518.
6. Leśniowski A.: Leczenie przetok kałowych zewnȩtrznych. Med., 1931, 24, 825-830.
7. Leśniowski A.: Przypadek przetok kałowych zewnȩtrznych. Pol. Przegl. Chir., 1930, 5-6, 689-690.
8. Leśniowski A.: W sprawie leczenia przetok kałowych zewnȩtrznych. Pol. Gaz. Lek., 1927, 43, 828-830.
9. Leśniowski A.: Choroby pȩcherza moczowego. Med., 1903, 48, 1079-1087.
10. Leśniowski A.: Chirurgie kiszek. Med., 1903, 26, 575-576.
11. Leśniowski A.: Choroby nerek i moczowodów. Med., 1903, 9, 193-211.
12. Leśniowski A.: Leczenie raka odbytnicy. Pol. Przegl. Chir., 1931, 2-3, 364-386.
13. Leśniowski A.: Leczenie gruźlicy narza̧dów wewnȩtrznych. Pol. Przegl. Chir., 1924, 14, 49-60.
14. Leśniowski A.: Kilka słów w sprawie kamicy przewodu żółciowego wspólnego. Med., 1928, 19-20, 399-401.
15. Leśniowski A.: O zastosowaniu krzywej ciśnienia krwi do celów rozpoznawczych. Pol. Przegl. Chir., 1933, 5-6, 801-802.
16. Leśniowski A.: O kamieniach w moczowodach. Przegl. Chir. Ginekol., 1910, 1, 51-68.
17. Leśniowski A.: Nowotwory kiszki grubej. Pol. Przegl. Chir., 1928, 3, 343-352.
18. Leśniowski A.: Przypadek owrzodzenia odbytu i odbytnicy niewiadomego pochodzenia (rak?). Pol. Przegl. Chir., 1930, 5-6, 686-689.
19. Leśniowski A.: Przypadek guza wa̧troby. Med., 1932, 3, 82.
20. Leśniowski A.: Przypadek guza gruźliczego w jamie brzucha. Pol. Przegl. Chir., 1927, 3, 527-528.
21. Leśniowski A.: W sprawie techniki laparotomijnej: o wlewach roztworu NaCl do otrzewny. Med., 1907, 38, 680-684.
22. Leśniowski A.: W sprawie operowania przepuklin uwiȩzłych. Gaz. Lek., 1917, 52, 541-545.
23. Leśniowski A.: W sprawie operowania brzusznego macicy dotkniȩtej rakiem. Med., 1906, 18, 332-336.
24. Leśniowski A.: W sprawie operowania brzusznego macicy dotkniȩtej rakíem. Med., 1906, 19, 351-354.
25. Leśniowski A.: W sprawie operowania brzusznego macicy dotkniȩtej rakiem. Med., 1906, 20, 373-379.
26. Leśniowski A.: Zapalenie wyrostka robaczkowego o niezwykłym umiejscowieniu. Pol. Przegl. Chir., 1923, 2, 206.
27. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nuñez G., Cho J.H.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 2001, 411, 603-606.
28. Núñez C., Barreiro M., Dominguez-Muñoz J.E., Lorenzo A., Zapata C., Peña A.S.: CARD15 mutations in patients with Crohn's disease in a homogeneous Spanish population. Am. J. Gastroenterol., 2004, 99, 450-456.
29. Annese V., Palmieri O., Latiano A., Ardizzone S., Castiglione F., Cottone M., D'Incà R., Gionchetti P., Papi C., Riegler G., Vecchi M., Andriulli A.: Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease Study. Dig. Liver Dis., 2004, 36, 121-124.
30. Hampe J., Cuthbert A., Croucher P.J., Mirza M.M., Mascheretti S., Fisher S., Frenzel H., King K., Hasselmeyer A., MacPherson A.J., Bridger S., van Deventer S., Forbes A., Nikolaus S., Lennard-Jones J.E., Foelsch U.R., Krawczak M., Lewis C., Schreiber S., Mathew C.G.: Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet, 2001, 357, 1925-1928.
31. Hampe J., Grebe J., Nikolaus S., Solberg C., Croucher P.J., Mascheretti S., Jahnsen J., Moum B., Klump B., Krawczak M., Mirza M.M., Foelsch U.R., Vatn M., Schreiber S.: Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet, 2002, 359, 1661-1665.
32. Heliö T., Halme L., Lappalainen M., Fodstad H., Paavola-Sakki P., Turunen U., Färkkilä M., Krusius T., Kontula K.: CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut, 2003, 52, 558-562.
33. Fellermann K., Wehkamp J., Herrlinger K.R., Stange E.F.: Crohn's disease: a defensin deficiency syndrome? Eur. J. Gastroenterol. Hepatol., 2003, 15, 627-634.
34. Wehkamp J., Fellermann K., Herrlinger K.R., Baxmann S., Schmidt K., Schwind B., Duchrow M., Wohlschläger C., Feller A.C., Stange E.F.: Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol., 2002, 14, 745-752.
35. Wehkamp J., Harder J., Weichenthal M., Mueller O., Herrlinger K.R., Fellermann K., Schroeder J.M., Stange E.F.: Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis., 2003, 9, 215-923.
36. Wehkamp J., Schwind B., Herrlinger K.R., Baxmann S., Schmidt K., Duchrow M., Wohlschläger C., Feller A.C., Stange E.F., Fellermann K.: Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig. Dis. Sci., 2002, 47, 1349-1355.
37. Editorial: Crohn's disease - 40 years on. Br. Med. J., 1978, 21, 1106-1107.
38. Watkinson G.: Sulphasalazine: a review of 40 years' experience. Drugs, 1986, 32, supl. 1, 1-11.
39. Baron J.H., Connell A.M., Lennard-Jones J.E., Avery Jones F: Sulphasalazine and Salicylazosulphadimidine in ulcerative colitis. Lancet, 1962, 279, 1094-1096.
40. Dissanayake A.S., Truelove S.C.: A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut, 1973, 14, 923-926.
41. Summers R.W., Switz D.M., Session Jr JT.: National Cooperative Crohn's Disease Study (NCCDS): result of drug treatment. Gastroenterology, 1979, 77, 847-869.
42. Malachow H., Ewe K., Brandes J.W.: European Cooperative Crohn's Disease Study (ECCDS): result of treatment. Gastroenterology, 1984, 86, 249-266.
43. Singleton J.W., Hanauer S.B., Gitnick G.L.: Mesalamine capsules for treatment of active Crohn's disease: result of a 16-week trial. Gastroenterology, 1993, 104, 1293-1301.
44. Sparberg M., Kirsner J.B.: Long-term corticosteroid therapy for regional enteritis: an analysis of 58 courses in 54 patients. Am. J. Dig. Dis., 1966, 11, 865-880.
45. Cooke W.T., Fielding J.F.: Corticosteroid or corticotrophin therapy in Crohn's disease (regional enteritis). Gut, 1970, 11, 921-927.
46. Munkholm P., Langholz E., Davidsen M., Binder V.: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut, 1994, 35, 360-362.
47. Stein R.B., Hanauer S.B.: Medical therapy for inflammatory bowel disease. Gastroenterol. Clin. North Am., 1999, 28, 297-321.
48. Rutgeerts P., Löfberg R., Malchow H., Lamers C., Olaison G., Jewell D., Danielsson A., Goebell H., Thomsen O.O., Lorenz-Meyer H.: A comparison of budesonide with prednisolone for active Crohn's disease. N. Engl. J. Med., 1994, 331, 842-845.
49. Bar-Meir S., Chowers Y., Lavy A., Abramovitch D., Sternberg A., Leichtmann G., Reshef R., Odes S., Moshkovitz M., Bruck R., Eliakim R., Maoz E., Mittmann U.: Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology, 1998, 115, 835-840.
50. Greenberg G.R., Feagan B.G., Martin F., Sutherland L.R., Thomson A.B., Williams C.N., Nilsson L.G., Persson T.: Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N. Engl. J. Med., 1994, 331, 836-841.
51. Greenberg G.R., Feagan B.G., Martin F., Sutherland L.R., Thomson A.B., Williams C.N., Nilsson L.G., Persson T.: Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology, 1996, 110, 45-51.
52. Brooke B.N., Javett S.L., Davison O.W.: Further experience with azathioprine for Crohn's disease. Lancet, 1970, 21, 1050-1053.
53. Rhodes J., Bainton D., Beck P.: Azathioprine in Crohn's disease. Lancet, 1970, 2, 1142.
54. Rhodes J., Bainton D., Beck P., Campbell H.: Controlled trial of azathioprine in Crohn's disease. Lancet, 1970, 2, 1273-1276.
55. Ewe K., Press A.G., Singe C.C., Stufler M., Hommel G., Meyer zum Büschenfelde K.H.: Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology, 1993, 105, 367-372.
56. Candy S., Wright J., Gerber M., Adams G., Gerig M., Goodman R.: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut, 1995, 37, 74-78.
57. Kozarek R.A., Patterson D.J., Gelfand M.D., Botoman V.A., Ball T.J., Wilske K.R.: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann. Intern. Med., 1989, 110, 353-356.
58. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., Greenberg G.R., Gillies R., Hopkins M.: Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med., 1995, 332, 292-297.
59. Feagan B.G., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., Greenberg G.R., Koval J., Wong C.J., Hopkins M., Hanauer S.B., McDonald J.W.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med., 2000, 342, 1627-1632.
60. Alfadhli A.A., McDonald J.W., Feagan B.G.: Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev., 2003, CD003459.
61. Nicholls S., Domizio P., Williams C.B., Dawnay A., Braegger C.P., MacDonald T.T., Walker-Smith J.A.: Cyclosporin as initial treatment for Crohn's disease. Arch. Dis. Child., 1994, 7, 243-247.
62. Brynskov J., Freund L., Nørby Rasmussen S., Lauritsen K., Schaffalitzky de Muckadell O., Williams C.N., MacDonald A.S., Tanton R., Molina F., Campanini M.C.: Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand. J. Gastroenterol., 1991, 26, 689-695.
63. Stange E.F., Modigliani R., Pena A.S., Wood A.J., Feutren G., Smith P.R.: European trial of cyclosporine in chronic active Crohn's disease: A 12-month study. The European Study Group. Gastroenterology, 1995, 109, 774-782.
64. Ambrose N.S., Allan R.N., Keighley M.R., Burdon D.W., Youngs D., Barnes P., Lennard-Jones J.E.: Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis. Colon Rectum, 1985, 28, 81-85.
65. Sutherland L., Singleton J., Sessions J., Hanauer S., Krawitt E., Rankin G., Summers R., Mekhjian H., Greenberger N., Kelly M.: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut, 1991, 32, 1071-1075.
66. Castiglione F., Rispo A., Di Girolamo E., Cozzolino A., Manguso F., Grassia R., Mazzacca G.: Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment. Pharmacol. Ther., 2003, 18, 1107-1112.
67. Steinhart A.H., Feagan B.G., Wong C.J., Vandervoort M., Mikolainis S., Croitoru K., Seidman E., Leddin D.J., Bitton A., Drouin E., Cohen A., Greenberg G.R.: Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology, 2002, 123, 33-40.
68. Arnold G.L., Beaves M.R., Pryjdun V.O., Mook W.J.: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm. Bowel Dis., 2002, 8, 10-15.
69. Colombel J.F., Lémann M., Cassagnou M., Bouhnik Y., Duclos B., Dupas J.L., Notteghem B., Mary J.Y.: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am. J. Gastroenterol., 1999, 94, 674-678.
70. Prantera C., Zannoni F., Scribano M.L., Berto E., Andreoli A., Kohn A., Luzi C.: An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am. J. Gastroenterol., 1996, 91, 328-332.
71. ten Hove T., Montfrans C., Peppelenbosch M.P., van Deventer S.J.: Inliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut, 2002, 50, 206-211.
72. Lügering A., Schmidt M., Lügering N., Pauels H.G., Domschke W., Kucharzik T.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspade-dependent pathway. Gastroenterology, 2001, 121, 1145-1157.
73. Braakman T.: A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn' disease. N. Engl. J. Med., 1997, 337, 1029-1035.
74. Akobeng A.K., Zachos M.: Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst. Rev., 2004, 1, CD003574.
75. Hanauer S.B., Feagan B.G., Lichtenstein G.R. i wsp.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002, 359, 1541-1549.
76. Prezent D.H., Rutgeerts P., Targan S. i wsp.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med., 1999, 340, 1399-1405.
77. Sands B., van Deventer S., Bernstein C. i wsp.: Long-term treatment of fistulising Crohn's disease: response to infliximab in the ACCENT II trial trough 54 weeks. Gastroenterology, 2002, 122, A81.
78. Agnholt J., Dahlerup J.F., Kaltoft K.: The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine, 2003, 23, 76-85.
79. D'Haens G., Swijsen C., Noman M., Lemmens L., Ceuppens J., Agbahiwe H., Geboes K., Rutgeerts P.: Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am. J. Gastroenterol., 2001, 96, 2564-2568.
80. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., Tremaine W.J., Johnson T., Diehl N.N., Zinsmeister A.R.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-control led trial. Gastroenterology, 2001, 121, 1088-1094.
81. Bauditz J., Wedel S., Lochs H.: Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut, 2002, 50, 196-200.
82. Bariol C., Meagher A.P., Vickers C.R., Byrnes D.J., Edwards P.D., Hing M., Wettstein A.R., Field A.: Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J. Gastroenterol. Hepatol., 2002, 17, 135-139.
83. Facchini S., Candusso M., Martelossi S., Liubich M., Panfili E., Ventura A.: Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J. Pediatr. Gastroenterol. Nutr., 2001, 32, 178-181.
84. Vasiliauskas E.A., Kam L.Y., Abreu-Martin M.T., Hassard P.V., Papadakis K.A., Yang H., Zeldis J.B., Targan S.R.: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology, 1999, 117, 1278-1287.
85. Ehrenpreis E.D., Kane S.V., Cohen L.B., Cohen R.D., Hanauer S.B.: Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology, 1999, 117, 1271-1277.
86. Sabate J.M., Villarejo J., Lemann M., Bonnet J., Allez M., Modigliani R.: An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment. Pharmacol. Ther., 2002, 16, 1117-1124.
87. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., Vyhnȧlek P., Zȧdorovȧ Z., Palmer T., Donoghue S.: Natalizumab for active Crohn's disease. N. Engl. J. Med., 2003, 348, 24-32.
88. Gordon F.H., Lai C.W., Hamilton M.I., Allison M.C., Srivastava E.D., Fouweather M.G., Donoghue S., Greenlees C., Subhani J., Amlot P.L., Pounder R.E.: A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology, 2001, 121, 268-274.
89. Yacyshyn B.R., Chey W.Y., Goff J., Salzberg B., Baerg R., Buchman A.L., Tami J., Yu R., Gibiansky E., Shanahan W.R.: Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut, 2002, 51, 30-36.
90. Yacyshyn B.R., Bowen-Yacyshyn M.B., Jewell L., Tami J.A., Bennett C.F., Kisner D.L., Shanahan W.R. Jr: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology, 1998, 114, 1133-1142.
91. Fedorak R.N., Gangl A., Elson C.O., Rutgeerts P., Schreiber S., Wild G., Hanauer S.B., Kilian A., Cohard M., LeBeaut A., Feagan B.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology, 2000, 119, 1473-1482.
92. van Deventer S.J., Elson C.O., Fedorak R.N.: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology, 1997, 113, 383-389.
93. Schreiber S., Fedorak R.N., Nielsen O.H., Wild G., Williams C.N., Nikolaus S., Jacyna M., Lashner B.A., Gangl A., Rutgeerts P., Isaacs K., van Deventer S.J., Koningsberger J.C., Cohard M., LeBeaut A., Hanauer S.B.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology, 2000, 119, 1461-1472.
94. Sandborn W.J., Present D.H., Isaacs K.L., Wolf D.C., Greenberg E., Hanauer S.B., Feagan B.G., Mayer L., Johnson T., Galanko J., Martin C., Sandler R.S.: Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology, 2003, 125, 380-388.
95. Neurath M.F., Wanitschke R., Peters M., Krummenauer F., Meyer zum Büschenfelde K.H., Schlaak J.F.: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut, 1999, 44, 625-8.
96. Janowitz H.D., Burrill B.: Crohn. Life and work. Falk Foundation e. V. 2000.